Membrane Proteome Chip Antibody Off-Target Screening Service

OverviewSolutionComparisonWorkflowWhy UsContact

Overview

In antibody drug development, specificity serves as the cornerstone of both safety and efficacy. However, accumulating evidence in recent years suggests that approximately 25-33% of antibody drugs—including those in clinical stages or already approved—exhibit unintended cross-reactivity.

Figure 1.Comparison of polyreactivity(nonspecific, charge/hydrophobicity-driven)and polyspecificity(specific off-target binding to unrelated proteins).(Cunninghamet al. 2021.)

These off-target interactions may not only trigger cellular toxicity and adverse events but also directly contribute to late-stage clinical failures or drug withdrawals.

More concerning is the fact that traditional specificity assessment methods, such as tissue cross-reactivity(TCR)studies based on immunohistochemistry, often miss a substantial number of off-target signals. Why? Because many off-target interactions occur between functionally unrelated membrane proteins that lack significant sequence homology, these interactions depend on the native conformation of the proteins and their membrane environment. Conventional approaches involving fixation, sectioning, or recombinant protein fragments are highly likely to obscure these critical off-target events, thereby delivering false-negative safety reports to development teams.

Creative Biogene's Native Membrane Proteome Screening Platform

Creative Biogene leverages an advanced high-throughput membrane protein array platform to perform systematic cross-reactivity screening of candidate antibodies under completely non-fixed, native conformation conditions. The platform features:

Coverage breadth: Contains >5,000 human membrane proteins (covering major classes such as GPCRs, ion channels, transporters, and receptors), expressed on live cell surfaces.
Detection method: Quantitative flow cytometry provides a sensitive and reproducible measurement, directly identifying unintended binding of antibodies to any membrane protein.
Physiological relevance: Avoids epitope masking or conformational distortion induced by fixation, enabling accurate capture of off-target events in a biologically relevant environment.

Comparison of Our Platform with Traditional Specificity Methods

Feature	Traditional Tissue Cross-reactivity(TCR)	Recombinant Protein Arrays	Our Platform
Antigen conformation	Tissue fixation+paraffin embedding, altered conformation❌	Recombinant fragments, often missing transmembrane regions❌	Live cell surface, native conformation✅ No fixation
Membrane protein representation	Tissue-dependent, low throughput	Limited(<500 proteins)	>5,000 full-length membrane proteins✅
Quantitative capacity	Semi-quantitative(staining intensity)	Moderate	Quantitative flow cytometry(MFI)✅ ≥background+3SD
Detection of non-specific cross-reactivity	High false-negative rate, especially for off-targets without homology❌	Insensitive to conformation-dependent epitopes❌	High sensitivity&specificity✅
Applicable stage	Late preclinical(IND-enabling)	Early discovery	All stages(lead→IND→post-market)✅

Typical Workflow

Why Choose Creative Biogene for This Service?

Regulatory and submission support: Platform data have been used by multiple partners as supplemental safety information in IND submissions, aligning with the FDA’s recent guidance recommending the use of more advanced, human-relevantin vitromethods for antibody specificity assessment.
Flexible compatibility with diverse modalities: Monoclonal antibodies, bispecific antibodies, ADCs, Fc fusion proteins, and even CAR-T targeting domains can all be screened.
Transparent pricing and technical support: Full-process scientist support from initial consultation to data interpretation;custom sublibraries available upon request(e.g., screening only immune checkpoint membrane proteins or the GPCRome).

Inquire Now

Off-target risk will not disappear on its own, but it can be identified well before you invest the next millions of dollars into development. The scientific team at Creative Biogene has accumulated extensive hands-on experience in membrane protein screening and antibody cross-reactivity assessment. We have collaborated with multiple drug development organizations across scenarios such as lead optimization, IND preparation, and biosimilar comparability studies, collectively identifying numerous off-target signals that were missed by traditional methods. Each collaboration reinforces our confidence that early, comprehensive native-conformation screening provides genuinely valuable input for decision-making.

We look forward to working with you to conduct a thorough risk assessment for your program.

Quick Inquiry